Neuroanaesthesia & neurocritical care
Early inhaled isoflurane sedation in neurocritical patients with invasive intracranial pressure monitoring: the NEURO-CONDA randomized pilot trial
Authors' conclusion
In this randomized pilot trial, early sedation with isoflurane was feasible and achieved reliable deep sedation without compromising intracranial or cerebral perfusion parameters in invasively monitored neurocritical patients without intracranial hypertension.
Study context
- Population
- Adult neurocritical patients requiring intracranial pressure (ICP) monitoring, without intracranial hypertension, tertiary ICU (May 2024-October 2025)19 with TBI
- Participants
- 30 patients
- Comparison
- Isoflurane vs propofol sedation
- Isofluranen = 15
- Propofoln = 15reference
- Primary endpoint
- Efficacy (RASS and BIS) and safety (serious adverse drug reactions, incl. sustained ICP elevation or CPP < 60 mmHg requiring increased vasopressor support)
Methodological detailsphase IV, open-label, parallel-group, pilot, single-centre (tertiary ICU)
- Phase IV
- Open-label
- Parallel-group
- Pilot
- Single-centre (tertiary ICU)
Primary result
As reported in the abstract
Sedation efficacy
Safety
Serious adverse drug reactions
- No serious adverse drug reactions (ADRs) occurred
- Intention-to-treat
ICP and cerebral perfusion pressure (CPP)
- ICP and CPP stable throughout without higher vasopressor doses in the isoflurane group
Original publication
Early inhaled isoflurane sedation in neurocritical patients with invasive intracranial pressure monitoring: the NEURO-CONDA randomized pilot trial. Crit Care. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →